FZ-AD004

Phase 1Small molecule

SShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

FZ-AD004 is one of 10 small molecule programs targeting Metastatic Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Solid TumorRecruiting

Metastatic Solid TumorPhase 1

Recruiting

Competition

Competitive Landscape

11 competitors in Metastatic Solid Tumor

#DrugCompanyPhaseTrials

Tukysa

Pfizer

Phase 2

1 2

Herceptin

OOrganon and Co

Phase 2

1 3

Trastuzumab Emtansine

SSeoul National University Bundang Hospital

Phase 2

1 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

2 5

Tuoyi

CCoherus Oncology, Inc.

Phase 1

1 6

Alimta

SShawn Eagle

Phase 1

1 7

Faslodex

FFresenius Kabi USA, LLC

Phase 1

1 8

5-Fluorouracil

Merck & Co.

Phase 1

1 9

CHS-114

CCoherus Oncology, Inc.

Phase 1

1 10

FZ-AD004

SShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Metastatic Solid Tumor

NCT05914545

Clinical

Trials by Indication[1]

Metastatic Solid Tumor1 trial

A PhaseⅠStudy to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of FZ-AD004 in Patients With Advanced Solid Tumors

Recruiting·SShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.·Phase 1·NCT05914545·121 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FZ-AD004. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FZ-AD004 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FZ-AD004. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

FZ-AD004

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Metastatic Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News